Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma"

回复：“NOTCH1：免疫治疗时代潜在的新生物标志物？”和“谨慎解读NOTCH1突变作为食管鳞状细胞癌替雷利珠单抗疗效预测生物标志物”